Pantalone KM, et al. - This pooled analysis was conducted to evaluate effectiveness and safety of dulaglutide 1.5 mg combined with insulin, categorized by subgroups of baseline glycated haemoglobin (HbA1c; ≤9% and >9% [≤74.9 and >74.9 mmol/mol]), age (<65 and ≥65 years), and duration of diabetes (<10 and ≥10 years) at 6 months in patients with type 2 diabetes (T2D). An aggregate of four hundred forty-five patients was involved in this investigation. On the basis of the data collected, it was concluded that dulaglutide 1.5 mg combined with basal or prandial insulin was efficacious for patients with T2D irrespective of age, duration of diabetes or baseline HbA1c.